NCT04886622 is a Phase 1 clinical trial of DT2216 in Solid Tumor, sponsored by Dialectic Therapeutics, Inc.

Who is sponsoring NCT04886622?

NCT04886622 is sponsored by Dialectic Therapeutics, Inc.

What drugs are being tested in NCT04886622?

Interventions in NCT04886622: DT2216.

What condition does NCT04886622 study?

NCT04886622 studies Solid Tumor, Hematologic Malignancy.

Is NCT04886622 still recruiting?

NCT04886622 is currently completed. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT04886622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of DT2216 in Relapsed/Refractory Malignancies

Completed Phase 1 Last updated 16 April 2025

What this trial tests

Phase 1 trial testing DT2216 in Solid Tumor in 20 participants. Completed in 30 June 2024.

Timeline

25 August 2021

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Dialectic Therapeutics, Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	25 August 2021
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	3 locations across United States

Drugs / interventions tested

DT2216 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →
Hematologic Malignancy — all drugs for Hematologic Malignancy →

Sponsor

Dialectic Therapeutics, Inc — full company profile →

Who can join

18 and older, any sex, with Solid Tumor or Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects with Relapsed or Refractory Malignancies

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

PROTAC targeted protein degraders: the past is prologue.
Békés M, Langley DR, Crews CM. · · 2022 · cited 2098× · PMID 35042991 · DOI 10.1038/s41573-021-00371-6
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Expanding PROTACtable genome universe of E3 ligases.
Liu Y, Yang J, Wang T, Luo M, et al · · 2023 · cited 117× · PMID 37845222 · DOI 10.1038/s41467-023-42233-2
Targeted protein degradation: advances in drug discovery and clinical practice.
Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy.
Vogler M, Braun Y, Smith VM, Westhoff MA, et al · · 2025 · cited 104× · PMID 40113751 · DOI 10.1038/s41392-025-02176-0
Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C, Morafraile EC, Alonso-Moreno C, Ocaña A. · · 2022 · cited 71× · PMID 35249548 · DOI 10.1186/s12943-022-01535-7
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X<sub>L</sub>-Specific Degrader DT2216.
Thummuri D, Khan S, Underwood PW, Zhang P, et al · · 2022 · cited 61× · PMID 34667112 · DOI 10.1158/1535-7163.mct-21-0474
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y, Ge S. · · 2022 · cited 53× · PMID 35331314 · DOI 10.1186/s13045-022-01251-1

Verify or expand the search:

Other trials of DT2216

Trials testing the same drug.

NCT06964009 — DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · Phase 1 · recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04886622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dialectic Therapeutics, Inc
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04886622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing